PDGFRA and central nervous system cancer: McNicholas et al. demonstrated that cells derived from a H3.3-G34R mutant glioma model containing the PDGFRA-C235Y mutation were not sensitive to the PDGFRA inhibitor avapritinib but were highly sensitive to the FGFR inhibitor infigratinib [58].